R.Coleman explains how the trial results can help plan treatment for women with metastatic breast cancer, highlighting advantages of a less intensified approach. The study was requested by regulatory bodies, originally with placebo in the comparator arm. Due to failed recruitment, the study design was changed. Further trials on bisphosphonates duration are no longer needed.